Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 1-Phenethylpiperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1-Phenethylpiperidine SCHEMBL917609 | 0.91 | SIGMAR1 (1.00) | SIGMAR1SLC6A3HRH3CYP1A2CYP3A4 | |
| SCHEMBL11589061 | 0.91 | SIGMAR1 (1.00) | SIGMAR1SLC6A3HRH3CYP1A2CYP3A4 | |
| 1-Phenethylpiperidine SCHEMBL4054824 | 0.91 | SIGMAR1 (1.00) | SIGMAR1SLC6A3HRH3CYP1A2CYP3A4 | |
| SCHEMBL11922748 | 0.91 | SIGMAR1 (1.00) | SIGMAR1SLC6A3HRH3CYP1A2CYP3A4 | |
| 1-Phenethylpiperidine SCHEMBL31229056 | 0.89 | SIGMAR1 (0.96) | SIGMAR1SLC6A3HRH3CYP1A2CYP3A4 | |
| 1-Phenethylpiperidine SCHEMBL11404041 | 0.89 | SIGMAR1 (0.96) | SIGMAR1SLC6A3HRH3CYP1A2CYP3A4 | |
| 1-Phenethylpiperidine SCHEMBL11507835 | 0.89 | SIGMAR1 (0.96) | SIGMAR1SLC6A3HRH3CYP1A2CYP3A4 | |
| 1-Phenethylpiperidine SCHEMBL27138909 | 0.89 | SIGMAR1 (0.96) | SIGMAR1SLC6A3HRH3CYP1A2CYP3A4 | |
| 1-Phenethylpiperidine SCHEMBL7524827 | 0.89 | SIGMAR1 (0.96) | SIGMAR1SLC6A3HRH3CYP1A2CYP3A4 | |
| 1-Phenethylpiperidine SCHEMBL27449208 | 0.89 | SIGMAR1 (0.96) | SIGMAR1SLC6A3HRH3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | disclosed |
| US-9844516-B2 | Sigma ligands for use in the prevention and/or treatment of post-operative pain | Laboratorios De Dr. Esteve (ES) | 2017-12-19 | — | — | US | disclosed |
| US-9789115-B2 | Use of sigma ligands in opioid-induced hyperalgesia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-10-17 | — | — | US | disclosed |
| US-9782483-B2 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2017-10-10 | — | — | US | disclosed |
| EP-2646025-B1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | ESTEVE LABOR DR (ES) | 2017-03-15 | — | — | EP | disclosed |
| WO-2016138135-A1 | SIGMA-1 RECEPTOR MODULATORS FOR TREATING HUNTINGTON'S DISEASE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-09-01 | — | — | WO | disclosed |
| EP-2531191-B1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | ESTEVE LABOR DR (ES) | 2016-03-30 | — | — | EP | disclosed |
| EP-2571501-B1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| US-20130324535-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-12-05 | — | — | US | disclosed |
| US-20130158033-A1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | disclosed |
| US-20130109692-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-05-02 | — | — | US | disclosed |
| US-20120302568-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-11-29 | — | — | US | disclosed |
| EP-2460519-A1 | Use of sigma ligands in bone cancer pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2415471-A1 | Use of sigma ligands in opioid-induced hyperalgesia | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2012-02-08 | — | — | EP | disclosed |
| EP-2388005-A1 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-11-23 | — | — | EP | disclosed |
| EP-2353598-A1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302568-A1 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN | OPRL1, OPRK1, SIGMAR1 | SIGMAR1 3/4885SLC6A3 601/4885MEN1 4826/4885 |
| US-20130158033-A1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | OPRL1, OPRK1, OPRM1 | SIGMAR1 5/4885SLC6A3 229/4885MEN1 4883/4885 |
| US-20130109692-A1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | SIGMAR1, SFN, TMEM97 | SIGMAR1 1/4885SLC6A3 461/4885MEN1 2012/4885 |
| US-20130324535-A1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | SIGMAR1, OPRL1, OPRK1 | SIGMAR1 1/4885SLC6A3 800/4885MEN1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.